Search results
Results from the WOW.Com Content Network
The classifications of substances as performance-enhancing substances are not entirely clear-cut and objective. As in other types of categorization, certain prototype performance enhancers are universally classified as such (like anabolic steroids), whereas other substances (like vitamins and protein supplements) are virtually never classified as performance enhancers despite their effects on ...
The oral bioavailability of amphetamine varies with gastrointestinal pH; [20] it is well absorbed from the gut, and bioavailability is typically 90%. [10] Amphetamine is a weak base with a p K a of 9.9; [ 189 ] consequently, when the pH is basic, more of the drug is in its lipid soluble free base form, and more is absorbed through the lipid ...
This is a list of investigational attention deficit hyperactivity disorder drugs, or drugs that are currently under development for clinical use in the treatment of attention deficit hyperactivity disorder (ADHD) but are not yet approved.
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Levoamphetamine [note 1] is a stimulant medication which is used in the treatment of certain medical conditions. [10] It was previously marketed by itself under the brand name Cydril, but is now available only in combination with dextroamphetamine in varying ratios under brand names like Adderall and Evekeo.
Attention deficit hyperactivity disorder management options are evidence-based practices with established treatment efficacy for ADHD.Approaches that have been evaluated in the management of ADHD symptoms include FDA-approved pharmacologic treatment and other pharmaceutical agents, psychological or behavioral approaches, combined pharmacological and behavioral approaches, cognitive training ...
[18] [20] At the time, Alles referred to the amphetamine compound as Benzedrine, a term derived from the name benzyl-methyl carbinamine. [21] In 1934, Smith, Kline & French made the first amphetamine pharmaceutical when they began selling a decongestant inhaler containing the volatile amphetamine free base under the trade name Benzedrine .
3-Methylmethcathinone (3-MMC), also known as metaphedrone, [4] is a designer drug from the substituted cathinone family. 3-MMC is a monoamine transporter substrate (a substance acted upon by monoamine transporters) that potently releases and inhibits the reuptake of dopamine and norepinephrine, as well as displaying moderate serotonin releasing activity.